Skip to content
10-Q

Quarterly Report

CIDARA THERAPEUTICS, INC.

0001610618-24-000142

← back to feed
Filed
Nov 7, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Nov 4, 2024 7.05M sh
Cash And Equivalents Q3 2024 · Sep 30, 2024 $127.39M
Cash And Equivalents Q3 2024 · Dec 31, 2023 $35.78M
Current Liabilities Q3 2024 · Sep 30, 2024 $44.34M
Current Liabilities Q3 2024 · Dec 31, 2023 $67.42M
Total Liabilities Q3 2024 · Sep 30, 2024 $46.7M
Total Liabilities Q3 2024 · Dec 31, 2023 $75.24M
Current Assets Q3 2024 · Sep 30, 2024 $156.77M
Current Assets Q3 2024 · Dec 31, 2023 $60.86M
Total Assets Q3 2024 · Sep 30, 2024 $162.33M
Total Assets Q3 2024 · Dec 31, 2023 $67.03M
Shares Diluted restated Q3 2024 · Sep 30, 2023 4.51M sh
Shares Diluted restated Q3 2024 · Sep 30, 2023 4.32M sh
Capex Q3 2024 · Sep 30, 2023 $327K
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$9.71M
Stockholders Equity restated Q3 2024 · Sep 30, 2023 −$5.89M
Stockholders Equity restated Q3 2024 · Jun 30, 2023 $2.42M
Stockholders Equity restated Q3 2024 · Mar 31, 2023 $15.11M
Stockholders Equity restated Q3 2024 · Dec 31, 2022 −$14.44M
Eps Diluted restated Q3 2024 · Sep 30, 2023 −$2.02
Eps Diluted restated Q3 2024 · Sep 30, 2023 −$4.56
Eps Basic restated Q3 2024 · Sep 30, 2023 −$2.02
Eps Basic restated Q3 2024 · Sep 30, 2023 −$4.56
Sga Expense Q3 2024 · Sep 30, 2023 $3.3M
Sga Expense Q3 2024 · Sep 30, 2023 $10.13M
Rd Expense restated Q3 2024 · Sep 30, 2023 $10.39M
Rd Expense restated Q3 2024 · Sep 30, 2023 $28.75M
Net Income restated Q3 2024 · Sep 30, 2023 −$9.11M
Net Income restated Q3 2024 · Sep 30, 2023 −$19.72M
Net Income restated Q3 2024 · Jun 30, 2023 −$13.62M
Net Income restated Q3 2024 · Mar 31, 2023 $3.01M
Operating Income restated Q3 2024 · Sep 30, 2023 −$4.47M
Operating Income restated Q3 2024 · Sep 30, 2023 −$18.36M